Agreed. Positive results from any one of a variety of avenues at this point can send this into a rocket like result. So important to see if this can help the world as a whole in getting past this cataclysmic event
“We have been working diligently since the close of our last financing to move forward with our plans for our first phase 2 clinical trial,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “NP-120 (Ifenprodil) represents a novel first in class treatment for both IPF and chronic cough and is an appropriate choice to be our lead compound.”